Gynecologic Oncology
A phase 1 study tested NeoVax, a vaccine tailored to each patient’s tumor mutations, in ten patients with platinum-sensitive high-grade epithelial ovarian cancer after chemotherapy, followed by delayed anti-PD-1 therapy. No unexpected safety signals emerged, and biomarker analyses suggested biological activity in six patients, alongside vaccine-specific immune responses. The small, uncontrolled trial assessed feasibility and safety; it does not establish clinical efficacy.
Published: 14 October 2026
Read the paper at Nature Medicine →